TOR Serine-Threonine Kinases

"TOR Serine-Threonine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that SIROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.

Descriptor ID	D058570
MeSH Number(s)	D08.811.913.696.620.682.700.931 D12.776.476.925
Concept/Terms	TOR Serine-Threonine Kinases TOR Serine-Threonine Kinases Kinases, TOR Serine-Threonine Serine-Threonine Kinases, TOR TOR Serine Threonine Kinases Target of Rapamycin Proteins Rapamycin Proteins Target mTOR Serine-Threonine Kinases Kinases, mTOR Serine-Threonine Serine-Threonine Kinases, mTOR mTOR Serine Threonine Kinases Mechanistic Target of Rapamycin Protein FK506 Binding Protein 12-Rapamycin Associated Protein 1 FK506 Binding Protein 12 Rapamycin Associated Protein 1 TOR Kinases FKBP12-Rapamycin Associated Protein Associated Protein, FKBP12-Rapamycin FKBP12 Rapamycin Associated Protein Protein, FKBP12-Rapamycin Associated FKBP12-Rapamycin Complex-Associated Protein Complex-Associated Protein, FKBP12-Rapamycin FKBP12 Rapamycin Complex Associated Protein Protein, FKBP12-Rapamycin Complex-Associated RAFT-1 Protein Protein, RAFT-1 RAFT 1 Protein Rapamycin Target Protein Protein, Rapamycin Target Target Protein, Rapamycin mTOR Protein Protein, mTOR

Below are MeSH descriptors whose meaning is more general than "TOR Serine-Threonine Kinases".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Serine-Threonine Kinases [D08.811.913.696.620.682.700]
TOR Serine-Threonine Kinases [D08.811.913.696.620.682.700.931]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Intracellular Signaling Peptides and Proteins [D12.776.476]
TOR Serine-Threonine Kinases [D12.776.476.925]

Below are MeSH descriptors whose meaning is related to "TOR Serine-Threonine Kinases".

Below are MeSH descriptors whose meaning is more specific than "TOR Serine-Threonine Kinases".

TOR Serine-Threonine Kinases
Mechanistic Target of Rapamycin Complex 1
Mechanistic Target of Rapamycin Complex 2

publications

Timeline | Most Recent

This graph shows the total number of publications written about "TOR Serine-Threonine Kinases" by people in this website by year, and whether "TOR Serine-Threonine Kinases" was a major or minor topic of these publications.

Bar chart showing 100 publications over 23 distinct years, with a maximum of 10 publications in 2011 and 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2004	0	2	2
2005	0	2	2
2006	0	2	2
2007	0	2	2
2008	0	8	8
2009	0	6	6
2010	1	7	8
2011	3	7	10
2012	2	4	6
2013	3	7	10
2014	4	3	7
2015	5	1	6
2016	5	3	8
2017	2	1	3
2018	0	3	3
2019	0	1	1
2020	0	1	1
2021	2	1	3
2022	1	6	7
2023	0	2	2
2024	1	0	1
2025	0	1	1

Below are the most recent publications written about "TOR Serine-Threonine Kinases" by people in Profiles.

Mohammadhosseini M, Enright T, Duvall A, Chitsazan A, Lin HY, Ors A, Davis BA, Nikolova O, Bresciani E, Diemer J, Craft K, Menezes AC, Merguerian M, Chong S, Calvo KR, Deuitch NT, Glushakow-Smith S, Gritsman K, Godley LA, Horwitz MS, Keel S, Castilla LH, Demir E, Mohammed H, Liu P, Agarwal A. Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder. Sci Transl Med. 2025 Jan 08; 17(780):eadn9832.

View in: PubMed
Coate KC, Dai C, Singh A, Stanley J, Covington BA, Bradley A, Oladipupo F, Gong Y, Wisniewski S, Sellick K, Spears E, Poffenberger G, Schornack AMR, Bustabad A, Rodgers T, Dey N, Shultz LD, Greiner DL, Yan H, Powers AC, Chen W, Dean ED. Interruption of glucagon signaling augments islet non-alpha cell proliferation in SLC7A2- and mTOR-dependent manners. Mol Metab. 2024 Dec; 90:102050.

View in: PubMed
Cohen J, Huang S, Koczwara KE, Woods KT, Ho V, Woodman KG, Arbiser JL, Daman K, Lek M, Emerson CP, DeSimone AM. Flavones provide resistance to DUX4-induced toxicity via an mTor-independent mechanism. Cell Death Dis. 2023 11 16; 14(11):749.

View in: PubMed
Malvi P, Chava S, Cai G, Hu K, Zhu LJ, Edwards YJK, Green MR, Gupta R, Wajapeyee N. HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B. Cell Rep Med. 2023 11 21; 4(11):101285.

View in: PubMed
Kim JM, Yang YS, Hong J, Chaugule S, Chun H, van der Meulen MCH, Xu R, Greenblatt MB, Shim JH. Biphasic regulation of osteoblast development via the ERK MAPK-mTOR pathway. Elife. 2022 08 17; 11.

View in: PubMed
Luciano AK, Korobkina ED, Lyons SP, Haley JA, Fluharty SM, Jung SM, Kettenbach AN, Guertin DA. Proximity labeling of endogenous RICTOR identifies mTOR complex 2 regulation by ADP ribosylation factor ARF1. J Biol Chem. 2022 10; 298(10):102379.

View in: PubMed
Cotton JL, Dang K, Hu L, Sun Y, Singh A, Rajurkar MS, Li Q, Wu X, Mao J. PTEN and LKB1 are differentially required in Gli1-expressing mesenchymal cells to suppress gastrointestinal polyposis. Cell Rep. 2022 07 19; 40(3):111125.

View in: PubMed
da Silva-Oliveira RJ, Gomes INF, da Silva LS, Lengert AVH, Laus AC, Melendez ME, Munari CC, Cury FP, Longato GB, Reis RM. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. Int J Mol Sci. 2022 Jul 14; 23(14).

View in: PubMed
Yu Q, Tu H, Yin X, Peng C, Dou C, Yang W, Wu W, Guan X, Li J, Yan H, Zang Y, Jiang H, Xia Q. Targeting Glutamine Metabolism Ameliorates Autoimmune Hepatitis via Inhibiting T Cell Activation and Differentiation. Front Immunol. 2022; 13:880262.

View in: PubMed
Varco-Merth BD, Brantley W, Marenco A, Duell DD, Fachko DN, Richardson B, Busman-Sahay K, Shao D, Flores W, Engelman K, Fukazawa Y, Wong SW, Skalsky RL, Smedley J, Axthelm MK, Lifson JD, Estes JD, Edlefsen PT, Picker LJ, Cameron CM, Henrich TJ, Okoye AA. Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy. J Clin Invest. 2022 05 16; 132(10).

View in: PubMed

People

Explore

Similar Concepts

Top Journals